Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2013 | 03-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -15,325 | -6,735 | -16,330 | -6,840 |
| Depreciation Amortization | 592 | 118 | 310 | 30 |
| Accounts payable and accrued liabilities | 886 | 1,339 | N/A | N/A |
| Other Working Capital | -695 | 135 | 2,320 | 450 |
| Other Operating Activity | -138 | -1,150 | 1,200 | 540 |
| Operating Cash Flow | $-14,680 | $-6,293 | $-12,500 | $-5,820 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | -57,935 | -14,923 | N/A | N/A |
| PPE Investments | -75 | -177 | -1,090 | -540 |
| Other Investing Activity | -50 | 0 | -100 | -380 |
| Investing Cash Flow | $-58,060 | $-15,100 | $-1,190 | $-920 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 57 | 1 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 89,240 | 17,320 |
| Financing Cash Flow | $57 | $1 | $89,240 | $17,320 |
| Beginning Cash Position | 86,190 | 86,190 | 10,640 | 60 |
| End Cash Position | 13,507 | 64,798 | 86,190 | 10,640 |
| Net Cash Flow | $-72,683 | $-21,392 | $75,540 | $10,580 |
| Free Cash Flow | ||||
| Operating Cash Flow | -14,680 | -6,293 | -12,500 | -5,820 |
| Capital Expenditure | -75 | -177 | N/A | N/A |
| Free Cash Flow | -14,755 | -6,470 | -12,500 | -5,820 |